Ушбу иш иқтибос қилган ишлар

189 та иш

Иш: Innovations in cancer immunotherapy: A comprehensive overview of recent breakthroughs and future directions

Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
Evanthia Galanis, Lynn C. Hartmann, William A. Cliby +17
Мақола20102 иқтибос
ABI
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty, Andrew R. Haas, Marcela V. Maus +9
Мақола20132 иқтибос
ABI
Oncolytic Viruses: Exploiting Cancer's Deal with the Devil
Larissa A. Pikor, John C. Bell, Jean‐Simon Diallo
Шарҳ мақола20152 иқтибос
ABI
Harnessing the immune system to improve cancer therapy
Nikos E. Papaioannou, Ourania V. Beniata, Panagiotis Vitsos +2
Шарҳ мақола20162 иқтибос
ABI
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment
Hila Magen, Eli Muchtar
Шарҳ мақола20162 иқтибос
ABI
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
Larysa Sanchez, Yucai Wang, David S. Siegel +1
Шарҳ мақола20162 иқтибос
ABI
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González +30
Мақола20172 иқтибос
ABI
Cytokines in Cancer Immunotherapy
Thomas A. Waldmann
Шарҳ мақола20172 иқтибос
ABI
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo‐Jack, Alice T. Shaw
Шарҳ мақола20172 иқтибос
ABI
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Flávia Castro, Ana Patrícia Cardoso, Raquel M. Gonçalves +2
Шарҳ мақола20182 иқтибос
ABI
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
Jung-Mao Hsu, Weiya Xia, Yi‐Hsin Elsa Hsu +14
Мақола20182 иқтибос
ABI
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Jong‐Ho Cha, Wenhao Yang, Weiya Xia +25
Мақола20182 иқтибос
ABI
Role of the immunosuppressive microenvironment in immunotherapy
Garth W. Tormoen, Marka R. Crittenden, Michael J. Gough
Шарҳ мақола20182 иқтибос
ABI
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jérôme Galon, Daniela Bruni
Шарҳ мақола20192 иқтибос
ABI
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Christopher M. Jackson, John Choi, Michael Lim
Шарҳ мақола20192 иқтибос
ABI
Extracellular Vesicle- and Extracellular Vesicle Mimetics-Based Drug Delivery Systems: New Perspectives, Challenges, and Clinical Developments
Prakash Gangadaran, Byeong‐Cheol Ahn
Шарҳ мақола20202 иқтибос
ABI
Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment
Lucia Lisi, Pedro Miguel Lacal, Maria Martire +2
Шарҳ мақола20212 иқтибос
ABI
VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment
Yueshui Zhao, Sipeng Guo, Jian Min Deng +13
Шарҳ мақола20222 иқтибос
ABI
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study
Yongxian Hu, Yali Zhou, Mingming Zhang +25
Мақола20222 иқтибос
ABI
GPRC5D-Targeted CAR T Cells for Myeloma
Sham Mailankody, Sean M. Devlin, Jonathan Landa +35
Мақола20222 иқтибос
ABI
Сарлавҳасиз
Бошқа1 иқтибос
ABI
Сарлавҳасиз
Бошқа1 иқтибос
ABI
Сарлавҳасиз
Бошқа1 иқтибос
ABI
Сарлавҳасиз
Бошқа1 иқтибос
ABI
Сарлавҳасиз
Бошқа1 иқтибос
ABI